Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy-Chinese experiences

Ju, Young-Tae; Hu, Yang; Sun, Si; Wang, J; Jiao, Shunchang

doi:10.4103/0019-509x.168954

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A moderate efficacy of everolimus was demonstrated for NSCLC in previous studies 22, 23. A combined use of EGFR‐TKIs and everolimus was found to be more effective than everolimus alone in one study 22. Four patients had a median PFS of 3.5 months in this study.…”

Section: Discussionmentioning

confidence: 47%

See 1 more Smart Citation

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma

Song

Zhang

2016

Cancer Medicine

View full text Add to dashboard Cite

PIK3CA mutation represents a clinical subset of diverse carcinomas. We explored the status of PIK3CA mutation and evaluated its genetic variability, treatment, and prognosis in patients with lung adenocarcinoma. A total of 810 patients with completely resected lung adenocarcinoma were recruited between 2008 and 2013. The status of PIK3CA mutation and other three genes, that is, EGFR mutation, KRAS mutation and ALK fusion were examined by reverse transcription‐polymerase chain reaction (RT‐PCR). Survival curves were plotted with the Kaplan–Meier method and log‐rank for comparison. Cox proportional hazard model was performed for multivariate analysis. Among the 810 patients, 23 cases of PIK3CA mutation were identified with a frequency of 2.8%. There were 14 men and 9 women with a median age of 61 years. Seventeen tumors revealed concurrent gene abnormalities of EGFR mutation (n = 12), KRAS mutation (n = 3), and ALK fusion (n = 2). Seven patients with EGFR & PIK3CA mutations recurred and administrated of EGFR‐TKIs yielded a median progression free‐survival of 6.0 months. Among four eviromous‐treated patients, stable disease was observed in three patients with a median Progression‐free survival (PFS) of 3.5 months. Patients with and without PIK3CA mutation had different overall survivals (32.2 vs. 49.6 months, P = 0.003). Multivariate analysis revealed that PIK3CA mutation was an independent predictor of poor overall survival (HR = 2.37, P = 0.017). The frequency of PIK3CA mutation was around 2.8% in the Chinese patients of lung adenocarcinoma. PIK3CA mutation was associated with reduced PFS of EGFR‐TKIs treatment and shorter overall survival.

show abstract

Section: Discussionmentioning

confidence: 47%

“…Clinically, everolimus, a mTOR inhibitor, has been widely prescribed for advanced renal carcinoma and breast carcinoma 20, 21. A moderate efficacy of everolimus was demonstrated for NSCLC in previous studies 22, 23. A combined use of EGFR‐TKIs and everolimus was found to be more effective than everolimus alone in one study 22.…”

Section: Discussionmentioning

confidence: 97%

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma

Song

Zhang

2016

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…To maximize the information available and to allow data analysis in those scientific papers that passed the bias assessment, it was agreed that it would be appropriate to split 3 of them in 2 [19][20][21] . Subsequently, they were considered as independent articles, so we can state that a total of 82 have been included in our analysis.…”

Section: Main Characteristics Of the Studies And Their Samplesmentioning

confidence: 99%

Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis

Rodríguez-Fuentes¹,

Pérez‐Sayáns²,

Carreras‐Presas³

et al. 2023

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

Drugs that Act on the Immune System

Meaney

2015

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy-Chinese experiences

Abstract: Everolimus was well tolerated, showing the modest clinical activity in heavily pretreated advanced NSCLC.

Cited by 3 publications

References 0 publications

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma

Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis

Drugs that Act on the Immune System

Contact Info

Product

Resources

About